If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

9. Ohtuvayre (ensifentrine) for COPD: Approved June 26, the inhaled medication is the first new type of maintenance COPD drug in over a decade. 10. Wakix (pitolisant) for pediatric narcolepsy ...

That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic obstructive pulmonary disease (COPD), which all ...

Pfizer has gained FDA approval for Eucrisa, a new ... drug is a phosphodiesterase-4 (PDE4) inhibitor targeting an anti-inflammatory mechanism already exploited by treatments for asthma, COPD ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...

When it was approved by the FDA in June ... moderate or severe exacerbations among COPD patients. Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential COPD treatment.

Specifically, the new definition emphasized the heterogeneity of COPD in terms of its underlying ... and that may soon have ...